IP Verse

Cladribine Regimen For Treating Multiple Sclerosis - EP2805723

The patent EP2805723 was granted to Merck Serono on Jan 17, 2018. The application was originally filed on Dec 20, 2005 under application number EP14001970A. The patent is currently recorded with a legal status of "Revoked".

EP2805723

MERCK SERONO
Application Number
EP14001970A
Filing Date
Dec 20, 2005
Status
Revoked
Oct 17, 2023
Grant Date
Jan 17, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 16, 2018ELKINGTON AND FIFE -

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0173059
DESCRIPTIONEP0626853
DESCRIPTIONUS5208327
DESCRIPTIONUS5506214
DESCRIPTIONUS6194395
DESCRIPTIONWO0064918
DESCRIPTIONWO2004028462
DESCRIPTIONWO2004087100
DESCRIPTIONWO2004087101
DESCRIPTIONWO9619229
DESCRIPTIONWO9619230
OPPOSITIONWO2004087101
SEARCHEP0626853
SEARCHWO2004087101

Non-Patent Literature (NPL) Citations (34) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BEUTLER ET AL., ACTA HEMATOL., (1994), vol. 91, pages 10 - 15-
DESCRIPTION- BEUTLER ET AL., PROC. NAT. CAD. SCI., (1996), vol. 93, pages 1716 - 1720-
DESCRIPTION- BEUTLER ET AL., SEMINARS IN HEMATOLOGY, (19951201), vol. 33, no. S1, pages 5 - 52-
DESCRIPTION- EVANS ET AL., ANN. NEUROLOGY, (1997), vol. 41, pages 125 - 132-
DESCRIPTION- GRIEB ET AL., ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, (1995), vol. 43, no. 5-6, pages 323 - 327-
DESCRIPTION- KURTZKE, NEUROLOGY, (1983), vol. 33, pages 1444 - 1452-
DESCRIPTION- LASSMANN ET AL., TRENDS MOL. MED., (2001), vol. 7, pages 115 - 121-
DESCRIPTION- LUBLIN; REINGOLD, NEUROLOGY, (1996), vol. 46, pages 907 - 911-
DESCRIPTION- LUCCHINETTI ET AL., CURR. OPIN. NEUROL., (2001), vol. 14, pages 259 - 269-
DESCRIPTION- MATTSON, EXPERT REV. NEUROTHERAPEUTICS, (2002), pages 319 - 328-
DESCRIPTION- MC DONALD ET AL., ANN. NEUROL., (2001), vol. 50, pages 121 - 127-
DESCRIPTION- MILLER ET AL., NEUROLOGY, (1996), vol. 47, no. 4, page 217-
DESCRIPTION- NOSEWORTHY ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, (2000), vol. 343, no. 13, pages 938 - 952-
DESCRIPTION- POSER ET AL., ANN. NEUROL., (1983), vol. 13, no. 3, pages 227 - 31-
DESCRIPTION- RICE, NEUROLOGY, (2000), vol. 54, no. 5, pages 1145 - 1155-
DESCRIPTION- ROBINS ET AL., J. AM. CHEM. SOC., (1984), vol. 106, page 6379-
DESCRIPTION- ROMINE ET AL., PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, (1999), vol. 111, no. 1, pages 35 - 44-
DESCRIPTION- SCHUMACHER ET AL., ANN. NYACAD. SCI.1965, (1965), vol. 122, pages 552 - 568-
DESCRIPTION- SELBY ET AL., CAN. J. NEUROL. SCI., (1998), vol. 25, pages 295 - 299-
DESCRIPTION- SIPE ET AL., LANCET, (1994), vol. 344, pages 9 - 13-
DESCRIPTION- SIPE ET AL., NEUROLOGY, (1984), vol. 34, pages 1368 - 1372-
DESCRIPTION- STELMASIAK ET AL., LABORATORY INVESTIGATIONS, (1998), vol. 4, no. 1, pages 4 - 8-
OPPOSITION- "Dose Response Information to Support Drug Registration, CPMP/ICH/378/95", EMEA, (19941100), pages 1 - 10, XP055525263-
OPPOSITION- GRIEB et al., "Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients", Arch Immunol Ther Exp (Warsz, (19950000), vol. 43, no. 5-6, pages 323 - 327, XP008047072-
OPPOSITION- "Results of a 96-week phase Ill trial of an oral short~coursedosing regimen in patients with relapsing-remitting multiplesclerosis", Clinical Study Report, (20150908), pages 1 - 4, XP055525259-
OPPOSITION- R. SCHMIDT, "Dose-finding studies in clinical drug developmen t", Eur J Clin Pharmacol, (19880000), vol. 34, pages 15 - 19, XP055350888-
OPPOSITION- SELBY et al., "Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis", Can. J. Neurol. Sci., (19980000), vol. 25, pages 295 - 299, XP055525281-
OPPOSITION- STELMASIAK et al., "A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting- relapsing multiple sclerosis", Medical Science Monitor, (19980404), vol. 4, no. 1, pages 4 - 8, XP008047060-
OPPOSITION- GIOVANNONI et al., "Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre", J Neurol Neurosrug Psychiatry, (20030000), vol. 74, no. 7, pages 946 - 949, XP055525276
OPPOSITION- BEUTLER et al., "Marrow suppression produced by repeated doses of cladribine", Acta. Haematol, (19940000), vol. 91, no. 1, pages 10 - 15, XP009183282
SEARCH- ELLISON GEORGE W ET AL, "Oral cladribine for multiple sclerosis", NEUROLOGY, & 49TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; BOSTON, MASSACHUSETTS, USA; APRIL 12-19, 1997, (1997), vol. 48, no. 3 SUPPL. 2, ISSN 0028-3878, pages A174 - A175, XP008047069 [A] 1-15 * the whole document *-
SEARCH- GRIEB PAWEL ET AL, "Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, (1995), vol. 43, no. 5-6, ISSN 0004-069X, pages 323 - 327, XP008047072 [XD] 1,7-9,13-16 * abstract * * page 324, column 1, paragraph 3 * * page 326, column 2, paragraph 3 *-
SEARCH- STELMASIAK Z ET AL, "A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting- relapsing multiple sclerosis", MEDICAL SCIENCE MONITOR 1998 POLAND, (1998), vol. 4, no. 1, ISSN 1234-1010, pages 4 - 8, XP008047060 [XD] 1,7-9,13-16 * abstract * * page 5, column 1, paragraph 2 - column 2, paragraph 1 * * page 7, column 1, paragraph 3 *-
SEARCH- LANGTRY H D ET AL, "Cladribine: A review of its use in multiple sclerosis", BIODRUGS 1998 NEW ZEALAND, (1998), vol. 9, no. 5, ISSN 1173-8804, pages 419 - 433, XP008047073 [X] 1,7-9,13-16 * page 422, column 1, paragraph 3 - page 423, column 1, paragraph 1 * * page 423, column 2, paragraphs 1,2 * * page 424, column 1, paragraph 5 * * table III * * page 430, column 1, paragraph 3 * * table IV * [A] 17

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents